February 12, 2025 · Form 4 insider transaction
Boyer David W. bought 6,401 shares of Neurocrine Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.; The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.